Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Multiplace Series
Hard-Shell Multiplace·2-18+ person
Pressure3 ATA
$150,000 - $400,000+
FDA-Approved Indication●●●●Strong Evidence
Hyperbaric Therapy for Sudden Hearing Loss
FDA-approved and time-sensitive — early HBOT treatment can significantly improve hearing recovery after sudden sensorineural hearing loss.
Key Takeaways
- ISSNHL is one of 14 FDA-approved indications for HBOT — covered by insurance.
- Treatment within 2 weeks of onset produces the best hearing recovery outcomes.
- A 2012 meta-analysis showed HBOT + steroids produced significantly better outcomes than steroids alone.
- ISSNHL affects 5,000–27,000 Americans annually and is a medical emergency.
- The cochlea has no direct blood supply — it depends on oxygen diffusion, making it ideal for HBOT.
- Benefit diminishes significantly if treatment begins more than 3 months after onset.
What is Sudden Sensorineural Hearing Loss?
Idiopathic sudden sensorineural hearing loss (ISSNHL) is defined as a rapid loss of 30 dB or more in hearing over 3 or fewer consecutive frequencies within 72 hours. It affects approximately 5,000–27,000 Americans annually and is a medical emergency — the sooner treatment begins, the better the outcome. ISSNHL is thought to result from vascular compromise to the cochlea (the inner ear's sensory organ), viral infection, or autoimmune inflammation. Standard treatment is high-dose oral corticosteroids, but approximately one-third of patients do not recover hearing with steroids alone. HBOT is the newest addition to the FDA's approved indications for HBOT, recognized in 2011.
How Hyperbaric Therapy Helps Sudden Sensorineural Hearing Loss
The cochlea is one of the most oxygen-demanding organs in the body relative to its size, yet it has no direct blood supply — it receives oxygen through diffusion from cochlear fluids. This makes it exquisitely sensitive to changes in oxygen levels. HBOT dramatically increases dissolved oxygen in the perilymph and endolymph (cochlear fluids), providing oxygen directly to hair cells and neural structures that have been compromised by vascular insufficiency. Additionally, HBOT reduces cochlear edema, modulates the inflammatory response, and may promote repair of damaged hair cells during the acute window. The effect is most pronounced when treatment begins within the first 2 weeks of symptom onset.
Recommended Protocol
Pressure
2.0–2.4 ATA
Sessions
10–20 sessions
Duration
90 minutes per session
What Does the Evidence Say?
●●●●Strong Evidence
A 2012 systematic review and meta-analysis published in Otology & Neurotology found that HBOT combined with steroids produced significantly better hearing outcomes than steroids alone for ISSNHL. Multiple studies confirm the time-dependent nature of the benefit: treatment within 2 weeks shows the most improvement, and benefit diminishes significantly after 3 months. A 2014 study from the Naval Medical Center San Diego showed HBOT salvage therapy recovered hearing in patients who failed initial steroid treatment. The UHMS added ISSNHL to its list of approved indications based on this accumulating evidence, and the FDA followed.
FDA-Approved Indication
Sudden Sensorineural Hearing Loss is one of the 14 conditions for which the FDA has approved hyperbaric oxygen therapy. Insurance coverage may be available with a physician prescription and treatment in an accredited facility.
Recommended Chambers for Sudden Sensorineural Hearing Loss
Based on the protocol requirements — minimum 2 ATA, Clinical Grade tier. Sorted by clinical credibility score.
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 34
Hard-Shell Monoplace·1-person
Pressure3 ATA
$50,000 - $90,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 36
Hard-Shell Monoplace·1-person
Pressure3 ATA
$55,000 - $95,000
Clinical GradeFDA Cleared
For Maximum Comfort
Perry Baromedical
Sigma 40
Hard-Shell Monoplace·1-person
Pressure3 ATA
$65,000 - $110,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma 40-II
Hard-Shell Multiplace·2-person
Pressure3 ATA
$100,000 - $160,000
Clinical GradeFDA Cleared
For Wound Care
Perry Baromedical
Sigma Elite
Hard-Shell Monoplace·1-person
Pressure3 ATA
$80,000 - $130,000
Frequently Asked Questions
How quickly should I start HBOT after sudden hearing loss?
As soon as possible — ideally within 2 weeks of symptom onset. The evidence shows the strongest benefit when treatment begins early. After 3 months, the likelihood of significant hearing recovery decreases substantially. If you experience sudden hearing loss, treat it as a medical emergency: see an ENT physician immediately and ask about HBOT within the first week if steroids alone are not producing improvement.
Does insurance cover HBOT for sudden hearing loss?
Yes. ISSNHL is an FDA-approved indication for HBOT. Medicare and most private insurers cover treatment when prescribed by a physician (typically an ENT specialist) and conducted in an accredited facility. The key is rapid diagnosis and referral — insurance approval delays should not prevent timely treatment.
Is HBOT used alone or with steroids?
HBOT is most commonly used in combination with corticosteroids, not as a standalone treatment. The best outcomes are seen with combined therapy. HBOT is also used as "salvage therapy" — for patients whose hearing has not recovered after initial steroid treatment. Some ENT physicians start both treatments simultaneously from the outset.
Related Conditions
Sources & References
- Bennett et al. (2012) — HBOT for idiopathic sudden sensorineural hearing loss and tinnitus, Cochrane Database of Systematic Reviews
- Murphy-Lavoie et al. (2012) — HBOT for ISSHL: a systematic review, Otology & Neurotology
- UHMS — Idiopathic Sudden Sensorineural Hearing Loss indication
- NIDCD — Sudden Deafness
Last updated: March 2026. Data sourced from manufacturer specifications, FDA databases, and published clinical research.
Ready to compare chambers?
Use our filterable directory to find chambers that match your protocol requirements.